Key result
Prolonged antiplatelet therapy significantly reduced vascular events by about one quarter among high-risk patients, including those with acute or past MI, stroke, or TIA (P<0.00001).
Why the study?
Does prolonged antiplatelet therapy reduce vascular events in high-risk and low-risk patients?
Population
145 randomized trials pooling about 70,000 'high risk' patients and 30,000 'low risk' subjects from the…
Comparison
Prolonged antiplatelet therapy, most widely… vs Control.
Design
Meta-analysis
Follow-up
Varied
Loading...
Prolonged antiplatelet therapy reduces vascular events across patient groups; establishes secondary prevention standard and directs subsequent trials.
Meta-Analysis (n=110,000)
Yes
Does prolonged antiplatelet therapy reduce vascular events in high-risk and low-risk patients?
Effect estimate: about one quarter reduction
p-value: p=<0.00001
Prolonged antiplatelet therapy, primarily medium-dose aspirin, significantly reduces the risk of vascular events and mortality in a wide range of high-risk patients, but its benefit in low-risk primary prevention remains unclear.
A 1994 study conducted a meta-analysis in High risk of occlusive vascular disease (n=110,000). Prolonged antiplatelet therapy vs. Control was evaluated on Vascular events (non-fatal myocardial infarctions, non-fatal strokes, or vascular deaths) (about one quarter reduction, p=<0.00001). Prolonged antiplatelet therapy significantly reduced vascular events by about one quarter among high-risk patients, including those with acute or past MI, stroke, or TIA (P<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: